Advertising Botox in the UK: what the rules actually say
Botulinum toxin is a prescription-only medicine in the UK, and advertising it to the public is prohibited — with the CAP Code, the Human Medicines Regulations and MHRA enforcement all in play.
In the United Kingdom, botulinum toxin — marketed as Botox, Vistabel, Dysport and others — is a prescription-only medicine. The consequence for anyone promoting treatment is direct and frequently misunderstood: it cannot be advertised to the public at all.
The two instruments
CAP Code rule 12.12 states that prescription-only medicines or treatments may not be advertised to the public. This governs marketing communications and is enforced by the Advertising Standards Authority.
Regulation 284 of the Human Medicines Regulations 2012 puts it in statute: a person may not publish an advertisement likely to lead to the use of a prescription-only medicine. This is enforced by the MHRA and carries considerably more weight than an advertising ruling.
Both apply to websites, social media, email lists and paid advertising alike. There is no carve-out for a practitioner’s own site, and none for organic social posts.
What this rules out
Naming the product. Listing it in a treatment menu. Pricing it. Before-and-after imagery labelled with the brand. Promotional offers on it. Hashtags naming it. Answering “what is Botox?” as page content that a prospective patient can find by searching for the product.
The test applied is not whether the wording is promotional in tone, but whether the communication is likely to lead to use of the medicine.
What is permitted
Advertising the consultation rather than the medicine. Describing what a treatment does rather than naming the product that does it — “anti-wrinkle injections”, “anti-wrinkle treatment”. Any reference to the prescription-only product itself must be incidental, balanced and factual, and it should not be something a prospective patient stumbles across while browsing.
The practical formulation the guidance keeps returning to: promote the assessment, not the drug.
Enforcement is active
CAP and the MHRA have issued a joint enforcement notice to the beauty and cosmetic services industry — an instrument aimed at a sector rather than a single advertiser, and directed at well over a hundred thousand businesses. After the stated compliance deadline the ASA moved to targeted enforcement, using monitoring technology to find non-compliant posts automatically, with referral to the MHRA or to professional regulators where an advertiser will not comply.
Social media has been the focus. This is not a dormant rule.
The sanctions available are graduated. The ASA can publish rulings naming the business, have paid search advertising removed, place a business on its list of non-compliant online advertisers, and refer to Trading Standards. For more serious breaches the MHRA can issue formal warnings and enforcement notices, and in the worst cases pursue criminal prosecution.
Why this belongs in a clinical reference
Because it is where the majority of practitioners get caught, and because the reasoning behind it is medical rather than bureaucratic. A prescription-only medicine implies an individual prescribing decision made after assessment. Advertising creates demand for a specific product before anyone has determined whether it is appropriate — which inverts the order that prescribing is supposed to follow.
This is a summary of published regulatory guidance, not legal advice. The ASA and MHRA publish the current position directly.
